GLPwatch
Papers (12034)
Page 185 of 201, ranked by citation count.
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.
- Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.
- Cellular loci for cagrilintide action identified.
- Semaglutide in Heart Failure With Preserved Ejection Fraction: Exploring Recent Evidence in Therapeutic Potential for the Obese Population.
- Selecting Pharmacologic Interventions for MASH.
- A clinical and experimental investigation of liraglutide effects on the brain-kidney axis.
- Current priorities in research on metabolic-associated fatty liver disease based on the results of EASL - 2024.
- [Can drug therapy for obstructive sleep apnea be expected after all?]
- Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
- Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction.
- GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.
- Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
- Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China.
- Gila Monster Lizard & Incretin-mimetics.
- Shaping the UK's long term relationship with tirzepatide.
- [GLP-1 receptor activation effects the p38MAPK signal pathway in hepatic stellate cells].
- Difficult to defeat obesity: An 8D approach.
- GLP-1-Based Therapies in Pain Medicine: A Narrative Review and Expert Opinion on Obesity-Related Low Back and Knee Pain.
- [Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day].
- Oral semaglutide in HFpEF: Real-world evidence and causal considerations.
- Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction.
- [Physiological analysis of various types of osmotic diuresis].
- Effect of Ozempic on Diabetic Nephropathy: A Case Report.
- [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
- Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.
- Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine.
- Insulin degludec + liraglutide (Xultophy°) in type 2 diabetes.
- Information pharmacists assist in the construction of GLP-1RA prescription review rules in a tertiary hospital in China.
- Reprint of: Impact of a pharmacist-led weight management service in a cardiology clinic.
- Prospecting the use of tirzepatide in combating obesity in Pakistan.
- Two Trials of Therapeutics for MASH with Liver Fibrosis.
- Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.
- PI3K/AKT/GSK3β regulatory axis in bone mesenchymal stem cells initiates diabetic myocardial infarction <i>via</i> miR-142-3p.
- Is Oral Semaglutide a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective.
- Tirzepatide.
- Clinical factors influencing the systolic blood pressure benefits of once-weekly semaglutide in patients with type 2 diabetes.
- Liraglutide subcutaneous injection for weight loss: where does it fit?
- Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes.
- Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide - a review.
- Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies.
- [Pharmacological treatment of obstructive sleep apnea syndrome].
- Hypercalcemia Induced by Tirzepatide and Calcium Supplementation: A Case Report.
- Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations.
- Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia.
- Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025.
- Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study.
- Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective.
- Anti-Inflammatory and Anabolic Effects of Liraglutide on 3D Inflammatory Osteoarthritic Spheroid and Scaffold Models of Human Chondrocytes.
- A RESPONSE TO: "COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES".
- A Subphenotype of Obesity With Reduced Enteroendocrine Glucagon-Like Peptide 1 Synthesis and Enhanced Tirzepatide Response.
- Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults.
- Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios.
- Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.
- Intranasal pramlintide matches intraperitoneal effects on food intake and gastric emptying in mice.
- Balancing oral sequential absorption barriers of semaglutide-loaded nanoparticles by optimization of surface glycocholic acid density.
- PYY<sub>3-36</sub> potentiates Semaglutide‑mediated mitochondrial modulation in MASLD.
- [Tirzepatide reduces body weight and improves symptoms in patients with obstructive sleep apnea syndrom.]
- Is There a Causal Link Between GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence.
- In brief: Wegovy HD - high-dose injectable semaglutide for weight loss.